Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 16 04:00PM ET
4.59
Dollar change
-0.69
Percentage change
-13.07
%
Index- P/E- EPS (ttm)-0.93 Insider Own8.07% Shs Outstand44.68M Perf Week-18.90%
Market Cap205.08M Forward P/E- EPS next Y-1.05 Insider Trans0.84% Shs Float41.07M Perf Month-8.75%
Income-41.47M PEG- EPS next Q-0.25 Inst Own12.13% Short Float8.30% Perf Quarter181.60%
Sales0.49M P/S418.53 EPS this Y-4.78% Inst Trans-10.89% Short Ratio1.91 Perf Half Y313.51%
Book/sh1.56 P/B2.94 EPS next Y-8.26% ROA-41.90% Short Interest3.41M Perf Year208.05%
Cash/sh1.67 P/C2.74 EPS next 5Y- ROE-47.07% 52W Range0.94 - 6.42 Perf YTD210.14%
Dividend Est.- P/FCF- EPS past 5Y35.42% ROI-58.24% 52W High-28.50% Beta2.00
Dividend TTM- Quick Ratio7.41 Sales past 5Y9.26% Gross Margin18.44% 52W Low388.30% ATR (14)0.63
Dividend Ex-Date- Current Ratio7.41 EPS Y/Y TTM-4.47% Oper. Margin-9305.74% RSI (14)44.46 Volatility12.47% 12.91%
Employees32 Debt/Eq0.03 Sales Y/Y TTM26.42% Profit Margin-8496.93% Recom1.00 Target Price10.50
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q-7.34% Payout- Rel Volume1.23 Prev Close5.28
Sales Surprise212.00% EPS Surprise21.38% Sales Q/Q21.87% EarningsFeb 29 AMC Avg Volume1.78M Price4.59
SMA20-16.78% SMA5021.34% SMA200124.22% Trades Volume2,159,046 Change-13.07%
Date Action Analyst Rating Change Price Target Change
Jan-05-22Initiated William Blair Outperform
Dec-08-21Initiated Robert W. Baird Outperform $19
Aug-09-21Resumed Maxim Group Buy $30 → $20
Oct-22-20Initiated H.C. Wainwright Buy $27
Oct-08-20Initiated Piper Sandler Overweight $25
Apr-08-24 04:05PM
Apr-01-24 08:50AM
Mar-21-24 07:55AM
Mar-14-24 08:50AM
08:08AM
04:05PM Loading…
Mar-06-24 04:05PM
12:00PM
Mar-01-24 10:12AM
Feb-29-24 07:40PM
04:07PM
04:06PM
04:05PM
Feb-26-24 08:00AM
Feb-22-24 08:00AM
Jan-17-24 10:30AM
04:05PM Loading…
Nov-20-23 04:05PM
Nov-02-23 04:05PM
Oct-26-23 04:05PM
Oct-23-23 08:45AM
Oct-11-23 09:35AM
Sep-26-23 04:05PM
Sep-05-23 08:00AM
Aug-09-23 04:05PM
Aug-07-23 04:05PM
Jul-24-23 05:09PM
Jun-20-23 05:22PM
Jun-05-23 08:00AM
May-04-23 04:10PM
Mar-28-23 08:00AM
Mar-06-23 08:15AM
07:11AM Loading…
Mar-04-23 07:11AM
Mar-02-23 04:10PM
Feb-27-23 08:15AM
Feb-02-23 08:00AM
Jan-10-23 08:00AM
Nov-21-22 10:52AM
Nov-08-22 08:15AM
Nov-03-22 04:10PM
Sep-12-22 04:05PM
Sep-10-22 07:30AM
Sep-08-22 08:15AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-04-22 04:10PM
Jul-05-22 08:30AM
Jul-02-22 09:10AM
May-17-22 08:30AM
May-09-22 08:02AM
May-05-22 04:10PM
Apr-12-22 04:00PM
Apr-08-22 01:05PM
01:05PM
Mar-22-22 09:05AM
Mar-17-22 06:32AM
Mar-08-22 04:45PM
Mar-01-22 08:30AM
Feb-24-22 04:10PM
Feb-17-22 03:02PM
Jan-31-22 06:22PM
Jan-20-22 03:44PM
01:46PM
Jan-18-22 05:00PM
Jan-13-22 09:17AM
Jan-11-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-10-21 08:30AM
Dec-08-21 09:38AM
Dec-03-21 08:30AM
Nov-18-21 07:00AM
Nov-14-21 07:18AM
Nov-09-21 08:30AM
Nov-04-21 04:15PM
Oct-28-21 03:06PM
Sep-30-21 08:36PM
Sep-15-21 06:37AM
Sep-08-21 04:00PM
Sep-07-21 08:30AM
Aug-25-21 08:15AM
Aug-06-21 04:15AM
Aug-05-21 04:15PM
Aug-03-21 03:01PM
Jul-12-21 08:00AM
Jul-06-21 08:30AM
Jun-28-21 08:30AM
Jun-10-21 12:30PM
Jun-08-21 08:30AM
May-24-21 08:35AM
02:09AM
May-20-21 08:30AM
May-06-21 04:10PM
Apr-23-21 11:39AM
Apr-12-21 06:00AM
Apr-10-21 08:30AM
08:30AM
Apr-08-21 08:30AM
Mar-25-21 01:41AM
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PACE GARY WDirectorDec 19 '23Buy1.3730,00041,100697,761Dec 19 06:39 PM